CareDx Posts 25% Revenue Growth in Q4 2025 Amid Rising Costs
Event summary
- CareDx reported $108 million in Q4 2025 revenue, up 25% YoY, with testing services volume increasing 17% YoY to 53,000 tests.
- GAAP net loss of $4 million in Q4 2025, compared to $88 million net income in Q4 2024, driven by higher operating expenses.
- Full-year 2025 revenue reached $380 million, a 14% YoY increase, with adjusted EBITDA of $32 million.
- Company repurchased $12 million in shares during Q4 2025, part of an $88 million buyback program for the year.
- Launched ImmuneScape through a strategic collaboration with 10x Genomics, expanding into multiomics discovery.
The big picture
CareDx's Q4 2025 results reflect strong demand for its testing services, but rising costs and a shift to non-GAAP profitability metrics signal challenges in maintaining margins. The company's strategic moves into multiomics and digital health solutions position it for long-term growth, though execution risks remain. With $200 million in cash reserves, CareDx has financial flexibility to navigate industry shifts and regulatory pressures.
What we're watching
- Revenue Diversification
- Whether CareDx can sustain growth in patient and digital solutions, which saw 47% YoY growth in Q4 2025.
- Cost Control
- How the company will manage rising operating expenses, which contributed to a GAAP net loss in Q4 2025.
- Strategic Expansion
- The pace at which CareDx can integrate new partnerships, like 10x Genomics, into its core business model.
Related topics